Discussion paper DP18025 Vaccine Progress, Stock Prices, and the Value of Ending the Pandemic Viral Acharya Timothy Johnson Suresh Sundaresan Steven Zheng 26 Mar 2023 Asset Pricing D6 D8 E21 E32 Q54
Discussion paper DP18026 Disasters with Unobservable Duration and Frequency: Intensified Responses and Diminished Preparednes Viral Acharya Timothy Johnson Suresh Sundaresan Steven Zheng 26 Mar 2023 Asset Pricing D6 D8 E21 E32 G10
Discussion paper DP18025 Vaccine Progress, Stock Prices, and the Value of Ending the Pandemic Viral Acharya Timothy Johnson Suresh Sundaresan Steven Zheng 26 Mar 2023 Asset Pricing D6 D8 E21 Q54
Discussion paper DP18026 Disasters with Unobservable Duration and Frequency: Intensified Responses and Diminished Preparednes Viral Acharya Timothy Johnson Suresh Sundaresan Steven Zheng 26 Mar 2023 Asset Pricing D6 D8 E21 E32 G10
VoxEU Column The value of a vaccine to end COVID-19 is worth between 5% and 15% of wealth Steven Zheng Timothy Johnson Suresh Sundaresan Viral Acharya 19 Jan 2021 COVID-19 Financial Markets
Discussion paper DP15558 The Value of a Cure: An Asset Pricing Perspective Viral Acharya Timothy Johnson Suresh Sundaresan Steven Zheng 11 Dec 2020 Financial Economics Macroeconomics and Growth Public Economics G12 D5 I1 Q54
Paper Article The Value of a Cure: An Asset Pricing Perspective Steven Zheng Timothy Johnson Suresh Sundaresan Viral Acharya 17 May 2022